NEOGEN CORP Q1 FY2027 earnings call

• Commercial Prowess: Management reports tangible progress in commercial execution, with regions benefiting from targeted customer engagement and competitive conversions. A new sales operating model is being rolled out globally, emphasizing account-level execution and disciplined pipeline management. Weekly KPI reviews have been enhanced to provide real-time visibility into performance.
• High Impact Innovation: Innovation remains the largest investment area for FY2027. The company announced a strategic collaboration with Henalea to apply hyperspectral imaging technology to food safety, aiming to simplify workflows and enable automation at the point of processing. The innovation approach now intentionally aligns commercial, technical, and product teams around specific customer needs.
• Operational Excellence: Focus is on building sustainable processes rather than short-term fixes. Sales and operations planning (SNOP) has been strengthened to improve global inventory visibility and optimization. Lean initiatives are active, with black belts leading continuous improvement projects across the organization.
• Petrofilm Manufacturing Transition: The transfer of Petrofilm manufacturing from third-party partners to Neogen’s Lansing facility is on track, beginning next month. The first SKU has achieved full validation (production, quality, stability), de-risking the program. Management emphasizes strict controls on customer continuity, safety stock levels, supplier management, and sequencing of the 17 SKUs involved.

Food Safety: Generated $163.2 million in revenue, representing 8.1% core growth (including ~400 bps from order timing). This segment accounted for approximately 73.3% of total revenue. Key drivers included 11% growth in indicator testing/culture media (led by Petri Film) and 7% growth in bacterial/general sanitation products. Animal Safety: Generated $59.6 million in revenue, representing 8% core growth (including ~100 bps from order timing). This segment accounted for approximately 26.7% of total revenue. Growth was led by veterinary instruments (needles/syringes) due to improved supply and strong performance in biosecurity products.

• Revenue Guidance: Raised to $885–$890 million for fiscal year 2027, reflecting higher expected revenue and momentum in both segments.
• Adjusted EBITDA Guidance: Raised to $181–$183 million for fiscal year 2027.
• Margin Trajectory: First half of FY2027 adjusted EBITDA margins are expected to be in line with Q1 results (approx. 18.7%), implying potential sub-20% margins in Q2 due to front-loaded investments in commercial infrastructure and national sales meetings. Full-year margins are guided to be roughly similar to fiscal year 2021 levels.
• Long-term Margin Expansion: Management expects to see margin improvements of 200–300 basis points in fiscal year 2029 as operational efficiency programs (inventory write-offs, sample collection improvements) take effect in the back half of the year and post-transition efficiencies are realized.
• Genomics Divestiture: The divestiture of the genomics business is included in current guidance; updates will follow closing. Net proceeds (~$140 million) are intended for debt reduction.

• Petrofilm Transition Execution: While de-risked by initial validations, the multi-quarter transfer of 17 SKUs carries risks regarding customer continuity, excessive inventory write-offs, and supplier management discipline.
• Inventory Management: Past issues with inventory management remain a focus area; although SNOP improvements are showing promise, the transition period requires careful balancing of safety stock to avoid unnecessary costs.
• Investment Headwinds: Near-term margin pressure exists due to deliberate investments in R&D, commercial capabilities, and enterprise systems, which may suppress profitability in the first half of the year before yielding long-term returns.
• Regulatory/Divestiture Uncertainty: The completion of the genomics business divestiture depends on regulatory approvals in Australia and New Zealand, with final decisions expected by end of December.

Q: Analyst asked if Neogen is already taking market share via competitive wins and how the new commercial model drives this. / A: CEO Mike Nassif and CJO Joe Freels confirmed early evidence of share gain, particularly through a new 'one team' approach for global strategic accounts. By assigning dedicated accountability to key global brands instead of fragmented regional reps, they saw 6.2% growth in these accounts in Q1, putting them on track for >8% annual growth. This shift from product-supply to solutions-partnering is driving tactical competitive conversions.

Q: Analyst asked about the trajectory of EBITDA margins, noting Q1 expansion vs. flat full-year guidance, and questioned the implication of Q1-aligned H1 margins. / A: CFO Bryan Riggsbee clarified that H1 margins will likely mirror Q1 (~18.7%) due to headwinds from upfront investments in commercial infrastructure (e.g., national sales meetings). However, full-year margins are guided to match FY2021 levels. Significant margin tailwinds from operational efficiency programs (inventory optimization, reduced write-offs) are weighted to the back half of the year, with full benefits expected by FY2029.

Q: Analyst inquired about the Petrofilm manufacturing transition, specifically inventory management, cost implications, and timeline for margin recovery. / A: CEO Nassif outlined four gating items: customer continuity, economic safety stock management, supplier onboarding, and disciplined SKU sequencing. CFO Riggsbee noted that duplicative costs are expected to rise YoY during the transition. Margin improvement of 200-300 bps is projected for FY2029 once transition efficiencies and operational programs are fully implemented.

Q: Analyst asked about the strategic partnership with Henalea (hyperspectral imaging) and its role in innovation/R&D. / A: CEO Nassif described the partnership as a key component of their 'high impact innovation' strategy. Hyperspectral sensors capture 100+ light bands (vs. 3 for standard cameras), allowing earlier detection of contaminants and simplifying downstream testing. This represents a move toward licensing novel technologies to create differentiated, automated solutions for food safety, with more partnerships anticipated.